Publicaciones en colaboración con investigadores/as de University of Southampton (11)

2019

  1. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

2018

  1. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542

  2. Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation

    Molecular and Cellular Proteomics, Vol. 17, Núm. 4, pp. 776-791

2017

  1. The dual Syk/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

    Clinical Cancer Research, Vol. 23, Núm. 9, pp. 2313-2324

2016

  1. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

    Haematologica

  2. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Leukemia, Vol. 30, Núm. 11, pp. 2179-2186

  3. Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease

    Leukemia, Vol. 30, Núm. 6, pp. 1301-1310

  4. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL

    Blood, Vol. 128, Núm. 6, pp. 816-826

  5. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

    Leukemia, Vol. 30, Núm. 2, pp. 351-360

2015

  1. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model

    Blood, Vol. 125, Núm. 26, pp. 4032-4041

2004

  1. NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder

    Cancer Research, Vol. 64, Núm. 8, pp. 2673-2676